Skip to main content
. 2021 Jun 22;43(2):1267–1272. doi: 10.1007/s10072-021-05399-5

Table 2.

Number of patients per injection, percentage responders and adverse events

MICCH Comparison groups
Non-MICCH ECH

First injection (n)

  Clin. relevant improvement (n, %)

  Attack freedom (n, %)

  Adverse eventsa (n, %)

47

28 (60%)

14 (30%)

15 (31%)

22

16 (73%)

7 (32%)

5 (23%)

49

37 (76%)

21 (43%)

11 (22%)

Second injection (n)

  Clin. relevant improvement (n, %)

  Attack freedom (n, %)

  Adverse events (n, %)

19

13 (68%)

3 (16%)

5 (25%)

3

2 (67%)

-

1 (33%)

9

8 (89%)

5 (56%)

2 (22%)

Third injection (n)

  Clin. relevant improvement (n, %)

  Attack freedom (n, %)

  Adverse events (n, %)

9

7 (78%)

2 (22%)

1 (10%)

2

2 (100%)

1 (50%)

1 (50%)

-

Fourth injection (n)

  Clin. relevant improvement (n, %)

  Attack freedom (n, %)

  Adverse events (n, %)

3

2 (67%)

1 (33%)

2 (67%)

1

1 (100%)

-

-

-

Fifth injection (n)

  Clin. relevant improvement (n, %)

  Attack freedom (n,%)

  Adverse events (n, %)

2

1 (50%)

1 (50%)

1 (50%)

1

1 (100%)

-

-

-

Sixth–eighth injectionb (n)

  Clin. relevant improvement (n, %)

  Adverse events (n, %)

1

1 (50%)

1 (50%)

-

-

-

-

aOnly minor adverse events occurred; bonly one patient received up to eight injections